Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Contraception|May 30, 2020
Reduction in use of cyproterone/ethinylestradiol (Diane-35 and generics) after risk minimization measures in the Netherlands, UK and ItalyFernie J A Penning-van Beest, Irene D Bezemer, Elisabeth Smits, et al.
Heart (British Cardiac Society)|April 5, 2024
Sex differences in the intensity of statin prescriptions at initiation in a primary care settingPauline A J Kiss, Alicia Uijl, Annemarijn R de Boer, et al.
The Annals of Pharmacotherapy|October 8, 2017
No Evidence for an Association Between Renal Function and Serious Bleeding Events in Patients Treated With Coumarins: A Population-Based StudyEline Houben, Elisabeth Smits, Jetty A Overbeek, et al.
Clinical Epidemiology|May 21, 2020
Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European CountriesEdith M Heintjes, Irene D Bezemer, Daniel Prieto-Alhambra, et al.
BMJ Open|March 26, 2024
Challenges and lessons learned from a long-term postauthorisation safety study programme of rivaroxaban in EuropeGunnar Brobert, Ana Ruigomez, Tania Schink, et al.
Pharmacoepidemiology and Drug Safety|January 2, 2021
Impact of EMA regulatory label changes on hydroxyzine initiation, discontinuation and switching to other medicines in Denmark, Scotland, England and the Netherlands: An interrupted time series regression analysisDaniel R Morales, Tatiana Macfarlane, Thomas M MacDonald, et al.
BMJ Open|February 1, 2023
Methodology of the brodalumab assessment of hazards: a multicentre observational safety (BRAHMS) studyMette Reilev, Peter Bjødstrup Jensen, Lise Skov Ranch, et al.
Research and Practice in Thrombosis and Haemostasis|March 18, 2026
Incidence and outcomes of major bleeding among first-time oral factor Xa inhibitor users: multinational observational cohort studiesAlexander T Cohen, Robert C Welsh, Jenneke Leentjens, et al.
Pharmacoepidemiology and Drug Safety|January 4, 2020
Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The NetherlandsDaniel R Morales, Steve V Morant, Thomas M MacDonald, et al.
British Journal of Clinical Pharmacology|July 16, 2020
Impact of EU regulatory label changes for diclofenac in people with cardiovascular disease in four countries: Interrupted time series regression analysisDaniel R Morales, Steven V Morant, Thomas M MacDonald, et al.
Pageof 3